Irish patients may lose out unless we change approach as global medicine supply chain undergoes seismic transformation ...
I can tell you that VDPHL01 has a unique profile unlike current FDA-approved treatments, which are associated with cardiac ...
HCW Biologics gets US FDA nod to begin first-in-human phase 1 trial of HCW9302 to treat patients with moderate-to-severe alopecia areata: Miramar, Florida Wednesday, February 5, 2 ...
Alys Pharmaceuticals, Inc. ("Alys"), an immune-dermatology focused company, today announces that the U.S. Food and Drug Administration (FDA) and Health Canada have cleared the Investigational New Drug ...
HCW Biologics (HCWB) announced that it has received clearance of its Investigational New Drug Application, IND, from the U.S. Food and Drug ...
This study will evaluate HCW9302 in patients with moderate to severe alopecia areataMIRAMAR, Fla., Feb. 03, 2025 (GLOBE ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results